Central Laboratories Featured Articles

31. 4 Steps To Help Sponsors Return Individual Patient Data 9/10/2024

    In part two of this series on individual patient data return (iPDR), Legacy Health Strategies experts offer four steps to help sponsors make iPDR a reality.

32. Returning Individual Trial Data To Patients: How And Why It Needs To Happen 9/9/2024

    Returning individual data to clinical trial participants is seen by many as "the right thing to do." Yet, its uptake is lacking. Legacy Health Strategies experts discuss why it's so important and how it can be achieved in part one of this two-part series.

33. Which Top HEOR Trends Will Have The Biggest Impact On Clinical Research? 9/6/2024

    ISPOR CEO Rob Abbott discusses Health Economics and Outcomes Research (HEOR) trends and how they're impacting clinical trials. 

34. These 3 Areas Need Risk Management Attention Now 8/29/2024

    Consultant Jessica Cordes and medical affairs expert Oscar Segurado team up to discuss the three key areas of risk in clinical trials.

35. Individual Participant Data Return Solutions And Strategies 8/22/2024

    Paula Boyles, external clinical trial data-sharing program lead for Pfizer and TransCelerate BioPharma member, shares the benefits of and strategies for individual patient data return (iPDR).

36. Why We Need Technology Consolidation In Clinical Trials 8/16/2024

    As more and more trial designs incorporate technologies that generate an immense amount of data, data managers struggle to continuously interconnect disparate systems and standardize data. All of this fuels the need for technology consolidation.

37. Automation: From Protocol Definition To Submission 8/12/2024

    Three members of Merck's global clinical data integration team discuss how automating various parts of the clinical trial process can improve data integrity.

38. From Data Chaos To Clarity: How To Modernize Clinical Trial Site Selection 7/19/2024

    The Pistoia Alliance introduces the ClinOps Ontology Project, an effort to establish a common language agreed upon by stakeholders across the industry to improve and standardize data collection and streamline site selection.

39. Unveiling The Importance Of Negative Results In Clinical Trials 7/11/2024

    BJEConsultants Chief Scientific Officer Bashar S. Shihabuddin, MD discusses negative clinical trial results and how they play a role in enhancing the generalizability of research findings.

40. Takeda Chooses Wearable To Improve Patient Experience & Data In Sleep Study 6/27/2024

    Takeda Head of the Orexin Franchise Development and Neuroscience Portfolio Strategy Elena Koundourakis explains why her team decided to pursue the use of DHTs and the benefits of doing so, for both the patients and the data accuracy.